Overview

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Status:
Not yet recruiting
Trial end date:
2023-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of MK-8189 in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.